is a Japanese

pharmaceutical company The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications to be administered to patients (or self-administered), with the aim to cure them, vaccinate them, or alleviate sympto ...

, and a subsidiary of Otsuka Holdings, which focuses on developing

cancer treatments Cancer can be treated by surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy (including immunotherapy such as monoclonal antibody therapy) and synthetic lethality, most commonly as a series of separate treatments (e.g. ...

. Taiho, headquartered in

Tokyo Tokyo (; ja, 東京, , ), officially the Tokyo Metropolis ( ja, 東京都, label=none, ), is the capital and largest city of Japan. Formerly known as Edo, its metropolitan area () is the most populous in the world, with an estimated 37.468 ...

Japan Japan ( ja, 日本, or , and formally , ''Nihonkoku'') is an island country in East Asia. It is situated in the northwest Pacific Ocean, and is bordered on the west by the Sea of Japan, while extending from the Sea of Okhotsk in the north ...

, is an R&D-driven specialty pharma focusing on the three fields of

oncology Oncology is a branch of medicine that deals with the study, treatment, diagnosis and prevention of cancer. A medical professional who practices oncology is an ''oncologist''. The name's etymological origin is the Greek word ὄγκος (''ó ...

allergies Allergies, also known as allergic diseases, refer a number of conditions caused by the hypersensitivity of the immune system to typically harmless substances in the environment. These diseases include hay fever, food allergies, atopic derma ...

and

immunology Immunology is a branch of medicineImmunology for Medical Students, Roderick Nairn, Matthew Helbert, Mosby, 2007 and biology that covers the medical study of immune systems in humans, animals, plants and sapient species. In such we can see there ...

, and

urology Urology (from Greek οὖρον ''ouron'' "urine" and '' -logia'' "study of"), also known as genitourinary surgery, is the branch of medicine that focuses on surgical and medical diseases of the urinary-tract system and the reproductive org ...

. Being Japan's second-largest

by prescription oral oncology sales, Taiho covers oncology related therapeutic areas including

stomach cancer Stomach cancer, also known as gastric cancer, is a cancer that develops from the lining of the stomach. Most cases of stomach cancers are gastric carcinomas, which can be divided into a number of subtypes, including gastric adenocarcinomas. Lymph ...

colorectal cancer Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, is the development of cancer from the colon or rectum (parts of the large intestine). Signs and symptoms may include blood in the stool, a change in bowel m ...

pancreatic cancer Pancreatic cancer arises when cell (biology), cells in the pancreas, a glandular organ behind the stomach, begin to multiply out of control and form a Neoplasm, mass. These cancerous cells have the malignant, ability to invade other parts of t ...

, and

breast cancer Breast cancer is cancer that develops from breast tissue. Signs of breast cancer may include a lump in the breast, a change in breast shape, dimpling of the skin, milk rejection, fluid coming from the nipple, a newly inverted nipple, or a re ...

. Taiho also engages in research and development, manufacturing, and the marketing of pharmaceutical products. The company is principally active in the prescription market, but also develops over-the-counter medication, and is a full member of the

Japan Pharmaceutical Manufacturers Association The Japan Pharmaceutical Manufacturers Association (JPMA) is the organization representing the research-based pharmaceutical industry operating in Japan. The JPMA has 74 members including 20 overseas affiliates (as of October 1, 2006). See also ...

(JPMA). As of March 2013, Taiho had over 2,500 employees worldwide. The company achieved approximately

US$ The United States dollar (symbol: $; code: USD; also abbreviated US$ or U.S. Dollar, to distinguish it from other dollar-denominated currencies; referred to as the dollar, U.S. dollar, American dollar, or colloquially buck) is the official ...

1.3 billion in revenue during the 2012

fiscal year A fiscal year (or financial year, or sometimes budget year) is used in government accounting, which varies between countries, and for budget purposes. It is also used for financial reporting by businesses and other organizations. Laws in many ...

History

1963 — Taiho Pharmaceutical Co., Ltd. established; Yukio Kobayashi appointed as president and representative director. Capital increased to ¥100 million A representative from each of the 49 distributors nationwide assumes the position of Board Member 1964 — In-house production plant established in Naruto, Tokushima Prefecture Nine new offices established throughout Japan, centered around the head office in

, as sales bases 1965 — Capital increased from ¥100 to ¥200 million 1969 — License with the

Soviet Union The Soviet Union,. officially the Union of Soviet Socialist Republics. (USSR),. was a transcontinental country that spanned much of Eurasia from 1922 to 1991. A flagship communist state, it was nominally a federal union of fifteen national ...

to introduce Futraful in Japan 1971 — Lyophilized formulation plant (seventh plant) completed in the Imagire Industrial Park in

Tokushima is a prefecture of Japan located on the island of Shikoku. Tokushima Prefecture has a population of 728,633 (1 October 2019) and has a geographic area of 4,146 km2 (1,601 sq mi). Tokushima Prefecture borders Kagawa Prefecture to the north, E ...

1974 — Proprietary Medicine Division established 1975 — Advertising strategy (TV ads) started for Tiovita Drink 1976 — Business alliance formed with Nichiban Co., Ltd., with

equity participation Equity may refer to: Finance, accounting and ownership *Equity (finance), ownership of assets that have liabilities attached to them ** Stock, equity based on original contributions of cash or other value to a business ** Home equity, the diff ...

by Taiho Pharmaceutical 1977 — Employee welfare facility Otsuka Amagi Mountain Villa completed 1978 — Business alliance formed with Kotai Kasei Co., Ltd., with equity participation by Taiho Pharmaceutical GMP-compliant injection drug plant completed within the

Plant; full plant integration also completed 1979 — Advertising strategy (TV ads) started for Solmack 1980 — GLP-compliant Tokushima Research and Development Laboratory and Safety Laboratory completed in Tokushima 1985 — 100% Taiho-financed Kotai Kasei head office plant completed; Kodama Laboratory set up on the plant premises 1986 — Head office moved to new building in Kanda, Chiyoda-ku, Tokyo State-of-the-art factory automation plant completed at Tokushima Plant 1987 — Synphar Laboratory established in

Alberta, Canada Alberta ( ) is one of the thirteen provinces and territories of Canada, provinces and territories of Canada. It is part of Western Canada and is one of the three Canadian Prairies, prairie provinces. Alberta is bordered by British Columbia to t ...

25th Anniversary Ceremony held in Tokyo and Tokushima Akihiko Otsuka becomes chairman and representative director 1989 — Formulation Research Laboratory completed 1990 — Drug Discovery Center, Seminar and Training Center, and Computer Center completed in Saitama Taiho Pharmaceutical purchases equity and participates in management of Shinsen Iyaku Co., Ltd. 1991 —

Okayama is the capital city of Okayama Prefecture in the Chūgoku region of Japan. The city was founded on June 1, 1889. , the city has an estimated population of 720,841 and a population density of 910 persons per km2. The total area is . The city is ...

Plant completed 1992 — 30th Anniversary Ceremony held in Tokyo Name of Shinsen Iyaku Co., Ltd. changed to Okayama Taiho Pharmaceutical Co., Ltd. President Yukio Kobayashi awarded honorary doctorate by the University of Alberta in Canada Kotai Kasei changed name to Taiho Fine Chemical 1994 — President Yukio Kobayashi awarded Japan's prestigious Medal with Yellow Ribbon 1995 — Taiho Fine Chemical merges with Taiho Pharmaceutical and starts operating as Saitama Plant President Yukio Kobayashi awarded the GreenDex Award by the Republic of Latvia 1996 — Collaborative research agreement signed for breast cancer therapeutics with SRI International (US) 1997 — Japanese and international GMP-compliant plant for new investigational drugs opens Clinical Research USA Office established in New York 1998 — Collaborative research and development agreement for angiogenesis inhibitor signed with Sugen, Inc. (U.S.A.) 1999 — Yukio Kobayashi, president and representative director of Taiho Pharmaceutical, becomes president and representative director of Otsuka Pharmaceutical Co., Ltd. 2000 — President Yukio Kobayashi becomes advisor to Otsuka Pharmaceutical 2001 — Yukio Kobayashi becomes chairman and representative director of Taiho Pharmaceutical Toru Usami becomes president and representative director of Taiho Pharmaceutical 2002 — Company History published in commemoration of the 40th Anniversary Taiho Pharma U.S.A., Inc. established in

New Jersey New Jersey is a state in the Mid-Atlantic and Northeastern regions of the United States. It is bordered on the north and east by the state of New York; on the east, southeast, and south by the Atlantic Ocean; on the west by the Delaware ...

in the U.S. 2003 — Marketing approval for TS-1 obtained in South Korea Inuyama Plant in Aichi Prefecture starts operations 2004 — Taiho Pharmaceutical signs a licensing agreement for new antiemetic palonosetron with Helsinn Healthcare SA (Switzerland) Research results on UFT adjuvant therapy for lung cancer published in

The New England Journal of Medicine ''The New England Journal of Medicine'' (''NEJM'') is a weekly medical journal published by the Massachusetts Medical Society. It is among the most prestigious peer-reviewed medical journals as well as the oldest continuously published one. His ...

(NEJM) Collaboration agreement in oncology signed with the University of Tokushima 2005 — Taiho Pharmaceutical signs a licensing agreement for anticancer agent Abraxane with American BioSciences Inc. 2007 — Annex to the head office completed Taiho Pharmaceutical holds a ceremony for the 45th anniversary of its founding in Tokyo Tenth plant newly established to manufacture anticancer granules and investigational drugs Data on TS-1 adjuvant therapy for gastric cancer published in NEJM 2008 — Otsuka Holdings established Results of a phase III trial on combination chemotherapy of TS-1 and cisplatin for advanced gastric cancer (SPIRITS) published in UK medical journal The Lancet Oncology Taiho Pharmaceutical of Beijing Co., Ltd., established 2009 — Marketing approval for TS-1 obtained in China Results of adjuvant chemotherapy for breast cancer treatment with UFT (N-SAS-BC01) published in the US's

Journal of Clinical Oncology The ''Journal of Clinical Oncology'' is a peer-reviewed medical journal published 3 times a month by the Lippincott Williams & Wilkins. It covers research on all aspects of clinical oncology. The journal was established in 1983 and the editor-in ...

(JCO) Taiho Pharmaceutical and PharmaMar (Spain) enter into a license agreement on anticancer agent, Yondelis Taiho History Museum completed at the Tokushima Plant Marketing approval obtained in Singapore for TS-ONE (TS-1) Taho Pharmaceutical acquires Tsukuba Research Institute from Banyu Pharmaceutical Co., Ltd 2010 — Research results from the FIRIS Study published in the electronic version of The Lancet Oncology Marketing approval for TS-1 obtained in Taiwan Research results for TS-1 on non-small cell lung cancer published in the digital version of the US's Journal of Clinical Oncology (JCO) 2011 — TS-1 approved in the EU as a treatment for advanced gastric cancer Taiho Pharmaceutical signs a licensing agreement on a new antiemetic combination agent with Helsinn Healthcare S.A. Taiho Pharmaceutical signs a distribution agreement with MSD K.K. for the anticancer compound vorinostat in Japan Taiho Pharmaceutical signs a co-development and commercialization agreement with Nordic Group BV for Teysuno in Europe Arrangements committee of European representative office established 2012 — Marketing approval for TS-ONE obtained in Thailand Marketing of Teysuno begins in Europe Masayuki Kobayashi becomes president and representative director Marketing approval for TS-ONE obtained in Hong Kong Marketing approval for TS-ONE obtained in Malaysia License agreement for anti-allergy drug bilastine signed with Spain-based Faes Farma S.A. 2013 — Research results on TS-1 against advanced cancer published in the digital edition of the Journal of Clinical Oncology (JCO) Kitajima Plant completed in Tokushima Prefecture

Parent Company

Otsuka Holdings Co., Ltd. The Otsuka Group is a global organization of 156

healthcare Health care or healthcare is the improvement of health via the prevention, diagnosis, treatment, amelioration or cure of disease, illness, injury, and other physical and mental impairments in people. Health care is delivered by health profe ...

companies with approximately 40,000 employees. Otsuka Holdings Co., Ltd., is the Group's holding company. The main operating companies are Otsuka Pharmaceutical Co., Ltd.; Otsuka Pharmaceutical Factory, Inc.; Taiho Pharmaceutical Co., Ltd.; Otsuka Warehouse Co., Ltd.; and Otsuka Chemical Co., Ltd.

Affiliated Companies

* Nichiban * OKAYAMA TAIHO Pharmaceutical Co., Ltd.

References

External links

Nichiban

OKAYAMA TAIHO Pharmaceutical Co., Ltd.
{{Authority control Pharmaceutical companies established in 1963 Otsuka Pharmaceutical

History

Parent Company

Affiliated Companies

Sponsored Drugs of Note

See also

References

External links